Capítulo 9
FEDERAL FOOD, DRUG, AND COSMETIC ACT
- SUBCHAPTER I— SHORT TITLE
- § 1
- § 2
- § 301Short title
- SUBCHAPTER II— DEFINITIONS
- § 321Definitions; generally
- § 321a“Butter” defined
- § 321b“Package” defined
- § 321cNonfat dry milk; “milk” defined
- § 321dMarket names for catfish and ginseng
- SUBCHAPTER III— PROHIBITED ACTS AND PENALTIES
- § 331Prohibited acts
- § 332Injunction proceedings
- § 333Penalties
- § 333aRepealed. Pub. L. 101–647, title XIX, § 1905, Nov. 29, 1990, 104 Stat. 4853
- § 334Seizure
- § 335Hearing before report of criminal violation
- § 335aDebarment, temporary denial of approval, and suspension
- § 335bCivil penalties
- § 335cAuthority to withdraw approval of abbreviated drug applications
- § 336Report of minor violations
- § 337Proceedings in name of United States; provision as to subpoenas
- § 337aExtraterritorial jurisdiction
- SUBCHAPTER IV— FOOD
- § 341Definitions and standards for food
- § 342Adulterated food
- § 343Misbranded food
- § 343–1National uniform nutrition labeling
- § 343–2Dietary supplement labeling exemptions
- § 343–3Disclosure
- § 343aRepealed. Pub. L. 106–554, § 1(a)(1) [title V, § 517], Dec. 21, 2000, 114 Stat. 2763, 2763A–73
- § 344Emergency permit control
- § 345Regulations making exemptions
- § 346Tolerances for poisonous or deleterious substances in food; regulations
- § 346aTolerances and exemptions for pesticide chemical residues
- § 346bAuthorization of appropriations
- § 347Intrastate sales of colored oleomargarine
- § 347aCongressional declaration of policy regarding oleomargarine sales
- § 347bContravention of State laws
- § 1
- § 348Food additives
- § 349Bottled drinking water standards; publication in Federal Register
- § 350Vitamins and minerals
- § 350aInfant formulas
- § 350a–1Protecting infants and improving formula supply
- § 350bNew dietary ingredients
- § 350cMaintenance and inspection of records
- § 350dRegistration of food facilities
- § 350eSanitary transportation practices
- § 350fReportable food registry
- § 350gHazard analysis and risk-based preventive controls
- § 350hStandards for produce safety
- § 350iProtection against intentional adulteration
- § 350jTargeting of inspection resources for domestic facilities, foreign facilities, and ports of entry; annual report
- § 350kLaboratory accreditation for analyses of foods
- § 350lMandatory recall authority
- § 350l–1Annual report to Congress
- § 350mRequirements for critical food
- SUBCHAPTER V— DRUGS AND DEVICES
- Part A— Drugs and Devices
- § 351Adulterated drugs and devices
- § 352Misbranded drugs and devices
- § 353Exemptions and consideration for certain drugs, devices, and biological products
- § 353aPharmacy compounding
- § 353a–1Enhanced communication
- § 353bOutsourcing facilities
- § 353cPrereview of television advertisements
- § 353dProcess to update labeling for certain generic drugs
- § 354Veterinary feed directive drugs
- § 1111DEFINITIONS.
- § 1112NOTIFICATION OF AGREEMENTS.
- § 1113FILING DEADLINES.
- § 1114DISCLOSURE EXEMPTION.
- § 1115ENFORCEMENT.
- § 1116RULEMAKING.
- § 1117SAVINGS CLAUSE.
- § 1118EFFECTIVE DATE.
- § 355New drugs
- § 355–1Risk evaluation and mitigation strategies
- § 355–2Actions for delays of generic drugs and biosimilar biological products
- § 355aPediatric studies of drugs
- § 355bAdverse-event reporting
- § 355cResearch into pediatric uses for drugs and biological products
- § 355c–1Report
- § 355dInternal committee for review of pediatric plans, assessments, deferrals, deferral extensions, and waivers
- § 355ePharmaceutical security
- § 355fExtension of exclusivity period for new qualified infectious disease products
- § 355gUtilizing real world evidence
- § 355hRegulation of certain nonprescription drugs that are marketed without an approved drug application
- § 356Expedited approval of drugs for serious or life-threatening diseases or conditions
- § 356–1Accelerated approval of priority countermeasures
- § 356–2Accelerated approval Council
- § 356aManufacturing changes
- § 356bReports of postmarketing studies
- § 356cDiscontinuance or interruption in the production of life-saving drugs
- § 356c–1Annual reporting on drug shortages
- § 356dCoordination; task force and strategic plan
- § 356eDrug shortage list
- § 356fHospital repackaging of drugs in shortage
- § 356gStandards for regenerative medicine and regenerative advanced therapies
- § 356hCompetitive generic therapies
- § 356iPrompt reports of marketing status
- § 356jDiscontinuance or interruption in the production of medical devices
- § 356kPlatform technologies
- § 356lAdvanced manufacturing technologies designation program
- § 357Qualification of drug development tools
- § 358Authority to designate official names
- § 359Nonapplicability of subchapter to cosmetics
- § 360Registration of producers of drugs or devices
- § 360aClinical trial guidance for antibiotic drugs
- § 360a–1Clinical trials
- § 360a–2Susceptibility test interpretive criteria for microorganisms
- § 360bNew animal drugs
- § 360b–1Priority zoonotic animal drugs
- § 360cClassification of devices intended for human use
- § 360c–1Reporting
- § 360dPerformance standards
- § 360ePremarket approval
- § 360e–1Pediatric uses of devices
- § 360e–3Breakthrough devices
- § 360e–4Predetermined change control plans for devices
- § 360fBanned devices
- § 360gJudicial review
- § 360g–1Agency documentation and review of significant decisions regarding devices
- § 360g–2Third party data transparency
- § 360hNotification and other remedies
- § 360h–1Program to improve the device recall system
- § 1
- § 1
- § 360iRecords and reports on devices
- § 360jGeneral provisions respecting control of devices intended for human use
- § 360kState and local requirements respecting devices
- § 360lPostmarket surveillance
- § 360mAccredited persons
- § 360nPriority review to encourage treatments for tropical diseases
- § 360n–1Priority review for qualified infectious disease products
- § 360n–2Ensuring cybersecurity of devices
- Part B— Drugs for Rare Diseases or Conditions
- § 360aaRecommendations for investigations of drugs for rare diseases or conditions
- § 360bbDesignation of drugs for rare diseases or conditions
- § 360ccProtection for drugs for rare diseases or conditions
- § 360ddOpen protocols for investigations of drugs for rare diseases or conditions
- § 360eeGrants and contracts for development of drugs for rare diseases and conditions
- § 360ee–1FDA rare neurodegenerative disease grant program
- § 360ffPriority review to encourage treatments for rare pediatric diseases
- § 360ff–1Targeted drugs for rare diseases
- Part C— Electronic Product Radiation Control
- § 360hhDefinitions
- § 360iiProgram of control
- § 360jjStudies by Secretary
- § 360kkPerformance standards for electronic products
- § 360llNotification of defects in and repair or replacement of electronic products
- § 360mmImports
- § 360nnInspection, records, and reports
- § 360ooProhibited acts
- § 360ppEnforcement
- § 360qqRepealed. Pub. L. 105–362, title VI, § 601(a)(2)(A), Nov. 10, 1998, 112 Stat. 3285
- § 360rrFederal-State cooperation
- § 360ssState standards
- Part D— Dissemination of Treatment Information
- § 360aaa to 360aaa–6Omitted
- Part E— General Provisions Relating to Drugs and Devices
- § 360bbbExpanded access to unapproved therapies and diagnostics
- § 360bbb–0Expanded access policy required for investigational drugs
- § 360bbb–0aInvestigational drugs for use by eligible patients
- § 360bbb–1Dispute resolution
- § 360bbb–2Classification of products
- § 360bbb–3Authorization for medical products for use in emergencies
- § 360bbb–3aEmergency use of medical products
- § 360bbb–3bProducts held for emergency use
- § 360bbb–3cExpedited development and review of medical products for emergency uses
- § 360bbb–4Countermeasure development, review, and technical assistance
- § 360bbb–4aPriority review to encourage treatments for agents that present national security threats
- § 360bbb–4bMedical countermeasure master files
- § 360bbb–5Critical Path Public-Private Partnerships
- § 360bbb–5aEmerging technology program
- § 360bbb–6Risk communication
- § 360bbb–7Notification
- § 360bbb–8Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments
- § 360bbb–8aOptimizing global clinical trials
- § 360bbb–8bUse of clinical investigation data from outside the United States
- § 360bbb–8cPatient participation in medical product discussion
- § 360bbb–8dNotification, nondistribution, and recall of controlled substances
- Part F— New Animal Drugs for Minor Use and Minor Species
- § 360cccConditional approval of new animal drugs for minor use and minor species and certain new animal drugs
- § 360ccc–1Index of legally marketed unapproved new animal drugs for minor species
- § 360ccc–2Designated new animal drugs for minor use or minor species
- Part G— Medical Gases
- § 360dddDefinitions
- § 360ddd–1Regulation of medical gases
- § 360ddd–2Inapplicability of drug fees to designated medical gases
- Part H— Pharmaceutical Distribution Supply Chain
- § 360eeeDefinitions
- § 360eee–1Requirements
- § 360eee–2National standards for prescription drug wholesale distributors
- § 360eee–3National standards for third-party logistics providers
- § 360eee–4Uniform national policy
- Part I— Nonprescription Sunscreen and Other Active Ingredients
- § 360fffDefinitions
- § 360fff–1Submission of requests
- § 360fff–2Eligibility determinations; data submission; filing
- § 360fff–3GRASE determination
- § 360fff–4Guidance; other provisions
- § 360fff–5Repealed. Pub. L. 116–136, div. A, title III, § 3854(b)(5), Mar. 27, 2020, 134 Stat. 456
- § 360fff–6Non-sunscreen time and extent applications
- § 360fff–7Report
- § 360fff–8Sunset
- SUBCHAPTER VI— COSMETICS
- § 361Adulterated cosmetics
- § 362Misbranded cosmetics
- § 363Regulations making exemptions
- § 364Definitions
- § 364aAdverse events
- § 364bGood manufacturing practice
- § 364cRegistration and product listing
- § 364dSafety substantiation
- § 364eLabeling
- § 364fRecords
- § 364gMandatory recall authority
- § 364hSmall businesses
- § 364iExemption for certain products and facilities
- § 364jPreemption
- SUBCHAPTER VII— GENERAL AUTHORITY
- Part A— General Administrative Provisions
- § 371Regulations and hearings
- § 372Examinations and investigations
- § 372aTransferred
- § 373Records
- § 374Inspection
- § 374aInspections relating to food allergens
- § 375Publicity
- § 376Examination of sea food on request of packer; marking food with results; fees; penalties
- § 377Revision of United States Pharmacopoeia; development of analysis and mechanical and physical tests
- § 378Advertising of foods
- § 379Confidential information
- § 379aPresumption of existence of jurisdiction
- § 379bConsolidated administrative and laboratory facility
- § 379cTransferred
- § 379dAutomation of Food and Drug Administration
- § 379d–1Conflicts of interest
- § 379d–2Policy on the review and clearance of scientific articles published by FDA employees
- § 379d–3Streamlined hiring authority
- § 379d–3aHiring authority for scientific, technical, and professional personnel
- § 379d–3bStrategic Workforce Plan and report
- § 379d–4Reporting requirements
- § 379d–5Guidance document regarding product promotion using the Internet
- Part B— Colors
- § 201[Definitions
- § 202[Effective Date
- § 203[Provisional Listings of Commercially Established Colors
- § 204[Effect on Meat Inspection and Poultry Products Inspection Acts
- § 379eListing and certification of color additives for foods, drugs, devices, and cosmetics
- Part C— Fees
- § 379fRecovery and retention of fees for freedom of information requests
- § 379gDefinitions
- § 379hAuthority to assess and use drug fees
- § 379h–1Fees relating to advisory review of prescription-drug television advertising
- § 379h–2Reauthorization; reporting requirements
- § 379iDefinitions
- § 379jAuthority to assess and use device fees
- § 379j–1Reauthorization; reporting requirements
- § 379j–11Definitions
- § 379j–12Authority to assess and use animal drug fees
- § 379j–13Reauthorization; reporting requirements
- § 379j–21Authority to assess and use generic new animal drug fees
- § 379j–22Reauthorization; reporting requirements
- § 379j–31Authority to collect and use fees
- § 379j–41Definitions
- § 379j–42Authority to assess and use human generic drug fees
- § 379j–43Reauthorization; reporting requirements
- § 379j–51Definitions
- § 379j–52Authority to assess and use biosimilar biological product fees
- § 379j–53Reauthorization; reporting requirements
- § 379j–61Definitions
- § 379j–62Authority to assess and use outsourcing facility fees
- § 379j–71Definitions
- § 379j–72Authority to assess and use OTC monograph fees
- § 379j–73Reauthorization; reporting requirements
- Part D— Information and Education
- § 379kInformation system
- § 379k–1Electronic format for submissions
- § 379lEducation
- Part E— Environmental Impact Review
- § 379oEnvironmental impact
- Part F— National Uniformity for Nonprescription Drugs and Preemption for Labeling or Packaging of Cosmetics
- § 379rNational uniformity for nonprescription drugs
- § 379sPreemption for labeling or packaging of cosmetics
- Part G— Safety Reports
- § 379vSafety report disclaimers
- Part H— Serious Adverse Event Reports
- § 379aaSerious adverse event reporting for nonprescription drugs
- § 379aa–1Serious adverse event reporting for dietary supplements
- Part I— Reagan-Udall Foundation for the Food and Drug Administration
- § 379ddEstablishment and functions of the Foundation
- § 379dd–1Location of Foundation
- § 379dd–2Activities of the Food and Drug Administration
- SUBCHAPTER VIII— IMPORTS AND EXPORTS
- § 381Imports and exports
- § 382Exports of certain unapproved products
- § 383Office of International Relations
- § 384Importation of prescription drugs
- § 384aForeign supplier verification program
- § 384bVoluntary qualified importer program
- § 384cInspection of foreign food facilities
- § 384dAccreditation of third-party auditors
- § 384eRecognition of foreign government inspections
- § 384fStrengthening FDA and CBP coordination and capacity
- § 384gRestricting entrance of illicit drugs
- SUBCHAPTER IX— TOBACCO PRODUCTS
- § 387Definitions
- § 387aFDA authority over tobacco products
- § 387a–1Final rule
- § 387bAdulterated tobacco products
- § 387cMisbranded tobacco products
- § 387dSubmission of health information to the Secretary
- § 387eAnnual registration
- § 387fGeneral provisions respecting control of tobacco products
- § 387f–1Enforcement action plan for advertising and promotion restrictions
- § 387gTobacco product standards
- § 387hNotification and other remedies
- § 387iRecords and reports on tobacco products
- § 387jApplication for review of certain tobacco products
- § 387kModified risk tobacco products
- § 387lJudicial review
- § 387mEqual treatment of retail outlets
- § 387nJurisdiction of and coordination with the Federal Trade Commission
- § 387oRegulation requirement
- § 387pPreservation of State and local authority
- § 387qTobacco Products Scientific Advisory Committee
- § 387rDrug products used to treat tobacco dependence
- § 387sUser fees
- § 387tLabeling, recordkeeping, records inspection
- § 387uStudies of progress and effectiveness
- § 387vReporting on tobacco regulation activities
- SUBCHAPTER X— MISCELLANEOUS
- § 391Separability clause
- § 392Exemption of meats and meat food products
- § 393Food and Drug Administration
- § 393aOffice of Pediatric Therapeutics
- § 394Scientific review groups
- § 395Loan repayment program
- § 396Practice of medicine
- § 397Contracts for expert review
- § 398Notices to States regarding imported food
- § 399Grants to enhance food safety
- § 399aOffice of the Chief Scientist
- § 399bOffice of Women’s Health
- § 399cImproving the training of State, local, territorial, and tribal food safety officials
- § 399dEmployee protections
- § 399eNanotechnology
- § 399fEnsuring adequate information regarding pharmaceuticals for all populations, particularly underrepresented subpopulations, including racial subgroups
- § 399gFood and Drug Administration Intercenter Institutes
- § 399hNational Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing
- § 399iFood and Drug Administration Working Capital Fund
- § 399jAbraham Accords Office